The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. [electronic resource]
Producer: 20070330Description: 93-6 p. digitalISSN:- 1462-0324
- Adalimumab
- Adult
- Aged
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents -- therapeutic use
- Arthritis, Psoriatic -- drug therapy
- Arthritis, Rheumatoid -- drug therapy
- Etanercept
- Female
- Genotype
- Humans
- Immunoglobulin G -- therapeutic use
- Infliximab
- Male
- Middle Aged
- Polymorphism, Genetic
- Prognosis
- Promoter Regions, Genetic
- Receptors, Tumor Necrosis Factor -- therapeutic use
- Severity of Illness Index
- Spondylitis, Ankylosing -- drug therapy
- Treatment Outcome
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.